Novo Nordisk’s share prices took a hit on Monday following the release of uninspiring data from a late-stage trial of its obesity drug candidate, CagriSema. The results, revealed during the REDEFINE 2 trial, failed to position CagriSema as a stronger competitor against Eli Lilly’s Mounjaro, a significant player in the weight-loss drugs market.
About the Author
